An analyst from The Motley Fool suggests Pfizer (NYSE: PFE) stock is currently a strong buy-and-hold opportunity. While the company's shares have fallen nearly 40% over the past five years, they have risen 14% this year. The analyst notes Pfizer trades at 10 times its estimated future earnings and offers a dividend yield of approximately 6.1%. The company is diversifying through acquisitions, including oncology company Seagen and weight-loss drug berobenatide from Metsera, to strengthen long-term growth prospects.